Learning About ILARIS®—A Specific Treatment for CAPS
In June 2009, ILARIS® (canakinumab) was approved in the United States for the treatment of FCAS (Familial Cold Autoinflammatory Syndrome) and Muckle-Wells Syndrome (MWS), 2 conditions in a group of rare diseases called CAPS, in both adults and in children aged 4 years and older.
ILARIS® is the first and only CAPS treatment that is approved for use in both adults and in children aged 4 years and older.
CAPS is caused by an overproduction of IL-1β, also known as interleukin-1 beta, a protein that is part of the immune system. Buildup of IL-1β in body tissues causes the inflammation and symptoms of CAPS.
ILARIS® can help people suffering from CAPS by delivering a complete and long-lasting response.If you suffer from CAPS, or if you are a caregiver or a loved one of someone with CAPS, the following links may help you learn more about what CAPS is—and how ILARIS® can help:
- Facts About CAPS
- Is ILARIS® Right for You?
- How ILARIS® Works
- Response With ILARIS®
- What You Should Know About ILARIS®
- ILARIS® Patient Support Program
You will also find Helpful Resources that you can download and keep with you, like the ILARIS® Patient Brochure, and links to other online resources for CAPS.







![[Image: Novartis]s](/images/nova-btn-logo.jpg)